Last updated on July 2019

Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations


Brief description of study

A Phase I Study of LXH254 in Patients With Advanced Solid Tumors That Harbor MAPK Pathway Alterations.

Clinical Study Identifier: NCT02607813

Find a site near you

Start Over